Alzheimer's Drug Doesn't Appear To Slow Cognitive Decline

Here is a great dementia resource for caregivers and healthcare professinals,

Here is information on being the best caregiver you can be

Here are more interesting dementia brain boosting Corrier-journal.comactivities

Here is a dementia music activity


David Goodhue - AHN Reporter
Boston, MA (AHN) - A promising drug designed to treat Alzheimer's disease was shown not to slow the cognitive decline in people in the late stages of the brain disease, according to a report in the Journal of the American Medical Association.


Dr. Robert C. Green of the Boston University Schools of Medicine, said the drug, tarenflurbil, initially showed promising results in slowing the production of a peptide amino acid that is likely the cause of plaques in the brains of people with Alzheimer's disease.

But he said in a statement that in phase-3 of a recent trial, the drug did not offer better outcomes on a measure of cognitive decline compared to patients receiving a placebo.

Green also said that participants taking tarenflurbil experienced dizziness, upper respiratory tract infections and anemia more than people taking the placebo